Incyte Corp (INCY) FinancialsINCYIncyte Corp

Incyte Corp (INCY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is JAKAFI revenues, accounting for 48.8% of total sales, equivalent to $816.66M. Other significant revenue streams include OPZELURA revenues and JAKAVI product royalty revenues. Understanding this composition is critical for investors evaluating how INCY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Incyte Corp maintains a gross margin of 93.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 41.84%, while the net margin is 34.98%. These profitability ratios, combined with a Return on Equity (ROE) of 30.67%, provide a clear picture of how effectively INCY converts its operational activities into shareholder value.

In the context of the broader market, INCY competes directly with industry leaders such as ROIV and VTRS. With a market capitalization of $22.96B, it holds a significant position in the sector. When comparing efficiency, INCY's gross margin of 93.73% stands against ROIV's 80.31% and VTRS's 42.03%. Such benchmarking helps identify whether Incyte Corp is trading at a premium or discount relative to its financial performance.

Incyte has shown strong financial performance, with a gross margin of 93.73% in Q2 2026 and a net margin of 34.98%. The net income for Q2 2026 was $585.61 million, reflecting robust profitability.